Jivi®, a site-specifically PEGylated rFVIII, offers an enhanced PK profile1

Jivi® rFVIII levels remain elevated and sustained over time1

PK of Jivi was investigated in 29 severe hemophilia A patients (≥12 years of age) following a single 60 IU/kg dose (measured by chromogenic assay)2

17.9 hours2*
1.63 mL/h/kg2*
4060 IU/h/dL2*
Site-specifically PEGylated rFVIII
Reduces clearance while
maintaining full rFVIII function1,3,4
  • Mean values.2
  • AUC, area under the curve; PEG, polyethylene glycol; PK, pharmacokinetic; rFVIII, recombinant Factor VIII.